Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01631318 · ClinicalTrials.gov registry record · NA
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT01631318: Completed NA study, sponsored by Stanford University.
NCT01631318 is a NA study that has completed, run by Stanford University. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01631318, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment. Patients were selected as a possible participant in this study because they are identified as having liver metastases
Interventions
- PROCEDURE Dynamic contrast-enhanced ultrasound imaging
- DEVICE Optical Tracking Device
- DEVICE Electromagnetic Tracking Device
- DRUG Perflutren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-11-01 |
| Est. Completion | 2020-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01631318
The ClinicalTrials.gov registry entry for NCT01631318 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dynamic contrast-enhanced ultrasound imaging is the first listed.
NCT01631318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01631318 about?
NCT01631318 is a clinical study titled "Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases". Patients are invited to participate in a research study of liver perfusion (how blood flows to the liver over time). Researchers hope to learn whether perfusion characteristics of liver metastases may be predictive of response to treatment and whether liver perfusion characteristics can be used to f...
What is the current status of trial NCT01631318?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2012-11-01. Estimated completion is 2020-09-30.
What interventions are being tested in trial NCT01631318?
The interventions under investigation include: Dynamic contrast-enhanced ultrasound imaging (PROCEDURE), Optical Tracking Device (DEVICE), Electromagnetic Tracking Device (DEVICE), Perflutren (DRUG).
Who is sponsoring clinical trial NCT01631318?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.